Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors. 2021

Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
Department of Medical Oncology, ENETS Center of Excellence, IPC NET Center, Institut Paoli-Calmettes, Marseille, France; oziels@ipc.unicancer.fr.

OBJECTIVE FOLFOX (5-Fluorouracile and oxaliplatin) exhibits promising activity in advanced well-differentiated neuroendocrine tumors (NETs). This retrospective study aimed to analyze the outcome of metastatic enteropancreatic NETs patients treated with FOLFOX. METHODS We retrospectively identified patients treated with FOLFOX for NETs of enteropancreatic or unknown origin among those referred to our Regional Multidisciplinary Tumor Board. RESULTS Among 48 patients, most often pancreatic NETs (n=33, 68.8%), the median Ki67 index was 10%. The median number cycle of FOLFOX was 6 and median follow-up was 34.8 months. Disease control rate (DCR) was 83.3%. Median PFS and OS were 12.6 and 29.4 months respectively. Median chemotherapy break was 14.1 months. No significant difference was observed between PFS and the following criteria: Ki67 index, primary tumor site, alkaline phosphatase levels, primary tumor surgery and 18F-FDG PET positivity. CONCLUSIONS FOLFOX exhibits a high DCR and a short duration of treatment with a relative long chemotherapy break in patients with metastatic enteropancreatic NETs.

UI MeSH Term Description Entries
D007414 Intestinal Neoplasms Tumors or cancer of the INTESTINES. Cancer of Intestines,Intestinal Cancer,Cancer of the Intestines,Intestines Cancer,Intestines Neoplasms,Neoplasms, Intestinal,Cancer, Intestinal,Cancer, Intestines,Cancers, Intestinal,Cancers, Intestines,Intestinal Cancers,Intestinal Neoplasm,Intestines Cancers,Intestines Neoplasm,Neoplasm, Intestinal,Neoplasm, Intestines,Neoplasms, Intestines
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009944 Organoplatinum Compounds Organic compounds which contain platinum as an integral part of the molecule. Compounds, Organoplatinum
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005602 France A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris. Corsica,Saint Pierre and Miquelon,Miquelon and Saint Pierre,Miquelon and St. Pierre,St. Pierre and Miquelon

Related Publications

Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
October 2014, The New England journal of medicine,
Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
October 2014, The New England journal of medicine,
Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
October 2014, The New England journal of medicine,
Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
July 2014, The New England journal of medicine,
Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
January 2023, Journal of neuroendocrinology,
Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
January 2000, Digestion,
Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
January 2017, Molecular and clinical oncology,
Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
September 2020, Journal of the National Comprehensive Cancer Network : JNCCN,
Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
March 2012, Expert opinion on pharmacotherapy,
Sandrine Oziel-Taieb, and Christophe Zemmour, and Jean-Luc Raoul, and Laurent Mineur, and Flora Poizat, and Nathalie Charrier, and Gilles Piana, and Gerard Cavaglione, and Patricia Niccoli
August 2016, Endocrine,
Copied contents to your clipboard!